[go: up one dir, main page]

EP1288202A4 - Derives n-acyltetrahydroisoquinoline - Google Patents

Derives n-acyltetrahydroisoquinoline

Info

Publication number
EP1288202A4
EP1288202A4 EP01926061A EP01926061A EP1288202A4 EP 1288202 A4 EP1288202 A4 EP 1288202A4 EP 01926061 A EP01926061 A EP 01926061A EP 01926061 A EP01926061 A EP 01926061A EP 1288202 A4 EP1288202 A4 EP 1288202A4
Authority
EP
European Patent Office
Prior art keywords
lower alkyl
integer
optionally substituted
acyltetrahydroisochinolin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01926061A
Other languages
German (de)
English (en)
Other versions
EP1288202A1 (fr
Inventor
Koji Yamada
Masaaki Hirose
Hisashi Iwaasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Original Assignee
Banyu Phamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Phamaceutical Co Ltd filed Critical Banyu Phamaceutical Co Ltd
Publication of EP1288202A1 publication Critical patent/EP1288202A1/fr
Publication of EP1288202A4 publication Critical patent/EP1288202A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés représentés par la formule générale (I). Dans cette formule R1 et R4 sont chacun indépendamment hydrogène, alkyle inférieur, ou un élément semblable, R2 et R3 sont chacun indépendamment alcoxy inférieur ou alkyle inférieur, R5 est alkyle inférieur ou aralkyle, chacun d'eux pouvant être éventuellement substitués, R6 est hydrogène ou alkyle inférieur, X est O, S ou NH, m est un entier compris entre 0 et 3, n est un entier qui vaut 0 ou 1, et Ar est phényle ou hétéroaryle, chacun d'eux pouvant être éventuellement substitués. Ces composés présentent un antagonisme du récepteur d'orexine et conviennent pour le traitement des dérèglements de l'appétit, de l'obésité, des troubles du sommeil etc..
EP01926061A 2000-05-11 2001-04-27 Derives n-acyltetrahydroisoquinoline Withdrawn EP1288202A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000137923 2000-05-11
JP2000137923 2000-05-11
PCT/JP2001/003736 WO2001085693A1 (fr) 2000-05-11 2001-04-27 Dérivés n-acyltétrahydroisoquinoline

Publications (2)

Publication Number Publication Date
EP1288202A1 EP1288202A1 (fr) 2003-03-05
EP1288202A4 true EP1288202A4 (fr) 2003-07-02

Family

ID=18645611

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01926061A Withdrawn EP1288202A4 (fr) 2000-05-11 2001-04-27 Derives n-acyltetrahydroisoquinoline

Country Status (6)

Country Link
US (1) US6838465B2 (fr)
EP (1) EP1288202A4 (fr)
JP (1) JPWO2001085693A1 (fr)
AU (1) AU779266B2 (fr)
CA (1) CA2408343A1 (fr)
WO (1) WO2001085693A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB0126292D0 (en) * 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
DE60311101T2 (de) * 2002-07-09 2007-06-21 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido und 2,3-dihydro-2h-pyrrolo (2,1-b)-chinazolinon-derivate
JP4528125B2 (ja) 2002-10-11 2010-08-18 アクテリオン ファーマシューティカルズ リミテッド スルホニルアミノ−酢酸誘導体
GB0225884D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
EP1572133B1 (fr) * 2002-12-13 2008-04-09 Janssen Pharmaceutica N.V. Methode d'identification de modulateurs du recepteur de l'orexine 2 humain
EP1751111B1 (fr) 2004-03-01 2014-12-31 Actelion Pharmaceuticals Ltd. Dérivés de 1,2,3,4-tétrahydroisoquinoléine substitués
JP2008520643A (ja) * 2004-11-18 2008-06-19 ファイザー・プロダクツ・インク 反芻動物におけるエネルギーバランスの治療に有用な薬物およびプロドラッグ
US20060178307A1 (en) * 2005-01-26 2006-08-10 The Regents Of The University Of California Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
JP2008540549A (ja) * 2005-05-09 2008-11-20 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能調節用化合物
CA2644010A1 (fr) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Derives de tetrahydroisoquinoleine pour renforcer la fonction de la memoire
CA2647077A1 (fr) * 2006-04-26 2007-11-01 Actelion Pharmaceuticals Ltd Nouveaux derives de pyrazolo-tetrahydropyridine
EP2049110B1 (fr) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Diazépans pontés antagonistes du récepteur de l'oréxine
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
CA2659352A1 (fr) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd Derives de 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene en tant qu'antagonistes de recepteur d'orexine
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
AU2007337659A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
JP2010527924A (ja) 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
MX2009012610A (es) 2007-05-22 2009-12-11 Astellas Pharma Inc Compuesto de tetrahidroisoquinolina 1-sustituido.
WO2008150364A1 (fr) 2007-05-23 2008-12-11 Merck & Co., Inc. Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
DK2152690T3 (da) 2007-05-23 2012-05-07 Merck Sharp & Dohme Pyridylpiperidinorexin-receptorantagonister
SE531698C2 (sv) 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
WO2009007419A1 (fr) * 2007-07-12 2009-01-15 Respiratorius Ab Nouveaux carbamates d'isoquinoléine bronchodilatateurs
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
IE20070928A1 (en) * 2007-12-21 2009-09-30 Giuliani Int Ltd Multi target ligands
BRPI0821141A2 (pt) * 2007-12-21 2015-06-16 Hoffmann La Roche Derivados de heteroarila como antagonistas do receptor de orexina
DK2227455T3 (da) 2007-12-28 2012-01-23 Actelion Pharmaceuticals Ltd Trisubstitueret 3,4-dihydro-1H-isoquinolinforbindelse, fremgangsmåde til fremstillingen og dens anvendelse
KR20110036069A (ko) * 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
PL3093291T3 (pl) 2009-10-23 2019-11-29 Janssen Pharmaceutica Nv Dipodstawione oktahydropirolo[3,4-c]pirole jako modulatory receptora oreksyny
EP2504316A1 (fr) 2009-11-23 2012-10-03 MSD Oss B.V. Composés hétérocyliques en tant qu'antagonistes des récepteurs d'orexine
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120050A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013119639A1 (fr) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Pipéridines/prolines substituées en tant qu'antagonistes du récepteur de l'orexine
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2014170343A1 (fr) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Agents de dépolarisation et modulateurs du récepteur nicotinique de l'acétylcholine pour le traitement de troubles dopaminergiques
WO2016025669A1 (fr) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines en tant que modulateurs des récepteurs de l'orexine
BR112018016446B1 (pt) 2016-02-12 2024-02-06 Eolas Therapeutics, Inc. Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos
RS63296B1 (sr) 2016-03-10 2022-07-29 Janssen Pharmaceutica Nv Metode lečenja depresije korišćenjem antagonista receptora oreksin-2
EP3454857A1 (fr) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de maladies inflammatoires auto-immunes
CN106831573B (zh) * 2017-01-23 2019-05-24 南阳师范学院 (n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用
PT3818055T (pt) 2018-07-06 2022-05-25 Respiratorius Ab Publ Novas amidas broncodilatadoras hetero-ligadas
WO2022063094A1 (fr) * 2020-09-22 2022-03-31 南京明德新药研发有限公司 Dérivé de tétrahydroisoquinoléine et son utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675112A1 (fr) * 1994-03-31 1995-10-04 Bristol-Myers Squibb Company Inhibiteurs de farnésyl-protéine-transférase contenant l'imidazole
WO1996039384A1 (fr) * 1995-06-06 1996-12-12 Pfizer, Inc. (indole-2-carbonyl-)-glycinamides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
WO1999058533A1 (fr) * 1998-05-08 1999-11-18 Smithkline Beecham Plc Derives de phenyluree et de (phenylthio)uree

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569380B1 (fr) 1991-01-11 1997-05-28 Laboratoires Glaxo Sa Derives d'acridine
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
SK4592000A3 (en) 1997-10-31 2000-12-11 Basf Ag Novel carboxylic acid derivatives which carry amide side chains, production of said carboxylic acid derivatives and their use as endothelin receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675112A1 (fr) * 1994-03-31 1995-10-04 Bristol-Myers Squibb Company Inhibiteurs de farnésyl-protéine-transférase contenant l'imidazole
WO1996039384A1 (fr) * 1995-06-06 1996-12-12 Pfizer, Inc. (indole-2-carbonyl-)-glycinamides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
WO1999058533A1 (fr) * 1998-05-08 1999-11-18 Smithkline Beecham Plc Derives de phenyluree et de (phenylthio)uree

Also Published As

Publication number Publication date
JPWO2001085693A1 (ja) 2004-01-08
WO2001085693A1 (fr) 2001-11-15
US20040044031A1 (en) 2004-03-04
AU5265701A (en) 2001-11-20
US6838465B2 (en) 2005-01-04
EP1288202A1 (fr) 2003-03-05
CA2408343A1 (fr) 2002-11-07
AU779266B2 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
EP1288202A4 (fr) Derives n-acyltetrahydroisoquinoline
NO20034291D0 (no) 2-aminopropanolderivater
MY129613A (en) Cannabinoid receptor binding compounds
ATE283259T1 (de) 1,4-substituierte cyclische aminderivate
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
WO2001038324A3 (fr) Composes
TR200103764T2 (tr) Mutilin türevleri ve bunların antibakteriyeller olarak kullanımları
ATE270817T1 (de) Fungizide
EP1642880A4 (fr) Inhibiteur de proteines de la famille hsp90
ATE227719T1 (de) Heteroaryl-zyklische acetale
DE60127845D1 (de) Benzylidenthiazolidindione und ihre verwendung als antimykotische mittel
WO2005037785A3 (fr) Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide, et n-[azepan-2-yl) phenylmethyl]benzamide, leur preparation et leur application en therapeutique
ATE258930T1 (de) Dihydrobenzifurane
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
WO2003057671A1 (fr) Compose biaryle et son utilisation
DK1301503T3 (da) Coumarinderivater med COMT-inhiberende aktivitet
ATE282605T1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
WO2002057224A3 (fr) Synthese et activite antimicrobienne de nouvelles « amidines inversees » dicationiques
EP1632484A4 (fr) D riv de thiadiazoline
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
WO2002087587A3 (fr) Amines bicycliques fusionnees
CA2206125A1 (fr) Hydrazinophenylsulfonylurees n-substituees utilisees comme herbicides et regulateurs de croissance vegetale
WO2003014094A3 (fr) Heterocyclylarylsulfonamides
ATE123025T1 (de) 2-amino-n-(((4-(aminocarbonyl)pyrimidin-2- yl>amino>alkyl>-pyrimidin-4- carbonsäureamidderivate, ihre herstellung und ihre anwendung in der therapeutica.
GB9800845D0 (en) Cellulosic particles and methods of making them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: IWAASA, HISASHI,BANYU PHARMACEUTICAL CO., LTD

Inventor name: HIROSE, MASAAKI,BANYU PHARMACEUTICAL CO., LTD

Inventor name: YAMADA, KOJI,BANYU PHARMACEUT. CO., LTD.

A4 Supplementary search report drawn up and despatched

Effective date: 20030520

RIN1 Information on inventor provided before grant (corrected)

Inventor name: IWAASA, HISASHI,BANYU PHARMACEUTICAL CO., LTD

Inventor name: HIROSE, MASAAKI,BANYU PHARMACEUTICAL CO., LTD

Inventor name: YAMADA, KOJI,BANYU PHARMACEUT. CO., LTD.

17Q First examination report despatched

Effective date: 20060224

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080114